WOLVERINE ASSET MANAGEMENT LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAC2. A total of 7 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.4%.

Quarter-by-quarter ownership
WOLVERINE ASSET MANAGEMENT LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$8,378,083
+11.2%
7,792,0000.0%0.09%
+5.6%
Q2 2023$7,533,069
-6.9%
7,792,0000.0%0.09%
-7.3%
Q1 2023$8,092,9177,792,0000.10%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2023
NameSharesValueWeighting ↓
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 98,354,000$105,134,8202.32%
CSS LLC/IL 4,500,000$4,831,1730.32%
WOLVERINE ASSET MANAGEMENT LLC 7,792,000$8,378,0830.09%
CITIGROUP INC 262,000$280,4970.00%
JPMORGAN CHASE & CO 175,000$187,6880.00%
JANE STREET GROUP, LLC 60,000$64,2190.00%
CONCOURSE FINANCIAL GROUP SECURITIES, INC. 0$00.00%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders